Aleniglipron Phase 2 Body Composition Study

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Obesity, Overweight, or Chronic Weight Management

In brief

This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 40 weeks of treatment.

Key facts

Study ID
NCT07169942
Run by
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
People needed
71
Starts
2025-08-15
Expected to finish
2026-10-01
Last updated by the study team
2026-03-03

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.